春立医疗(01858)公布，于2025年11月11日，该公司订立(i)北京银行(大兴支行)结构性存款产品协议1， 同意使用其来自A股公开发行的临时闲置募集资金认购北京银行(大兴支行)的结构性存款产品，总金额 为人民币2.9亿元;(ii)北京银行(方庄支行)结构性存款产品协议1，同意使用其来自A股公开发行的临时闲 置募集资金认购北京银行(方庄支行)的结构性存款产品，总金额为人民币2.1亿元;及(iii)北京银行(方庄 支行)结构性存款产品协议2，同意使用其内部资源认购北京银行(方庄支行)的结构性存款产品，总金额 为人民币2.9亿元。 此外，于2025年9月26日，公司订立上海浦东发展银行(海淀园支行)结构性存款产品协议，同意使用其 内部资源认购上海浦东发展银行的结构性存款产品，总金额为人民币8500万元。上海浦东发展银行(海 淀园支行)结构性存款产品协议于本公告日期前已赎回。 ...

Core Viewpoint - Spring Medical (01858) has entered into multiple structured deposit agreements with Beijing Bank and Shanghai Pudong Development Bank, utilizing temporary idle funds raised from its A-share public offering for investment purposes [1] Group 1: Structured Deposit Agreements - The company has agreed to invest a total of RMB 2.9 billion in a structured deposit product with Beijing Bank (Daxing Branch) using idle funds from its A-share public offering [1] - Additionally, the company will invest RMB 2.1 billion in another structured deposit product with Beijing Bank (Fangzhuang Branch) from the same source [1] - The company has also committed RMB 2.9 billion to a second structured deposit product with Beijing Bank (Fangzhuang Branch) using internal resources [1] Group 2: Other Financial Agreements - On September 26, 2025, the company entered into a structured deposit agreement with Shanghai Pudong Development Bank (Haidian Park Branch), agreeing to invest RMB 85 million using internal resources [1] - The structured deposit agreement with Shanghai Pudong Development Bank (Haidian Park Branch) was redeemed prior to the announcement date [1]

Core Viewpoint - Spring Medical (01858.HK) has announced the establishment of structured deposit agreements with Beijing Bank, utilizing temporarily idle funds raised from its A-share public offering, totaling RMB 7.9 billion [1] Group 1: Structured Deposit Agreements - The company has entered into a structured deposit product agreement with Beijing Bank (Daxing Branch) for a total amount of RMB 290 million [1] - Additionally, a structured deposit product agreement with Beijing Bank (Fangzhuang Branch) has been established for a total amount of RMB 210 million [1] - The company also agreed to use internal resources to subscribe to another structured deposit product with Beijing Bank (Fangzhuang Branch) for a total amount of RMB 290 million [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 須予披露交易 (I)認購上海浦東發展銀行（海淀園支行）的結構性存款產品 (II)認購北京銀行（大興支行）的結構性存款產品 (III)認購北京銀行（方莊支行）的結構性存款產品 認購該等結構性存款產品 茲提述本公司日期為2025年3月31日的公告（「該公告」），內容有關（其中包括） 本公司認購北京銀行（方莊支行）及北京銀行（大興支行）的結構性存款產品。 誠如該公告所披露，於2025年3月31日，本公司訂立(i)北京銀行（大興支行）結構 性存款產品協議，同意使用其來自A股公開發行的臨時閒置募集資金認購北京 銀行（大興支行）的結構性存款產 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 須予披露交易 (I)認購上海浦東發展銀行（海淀園支行）的結構性存款產品 (II)認購北京銀行（大興支行）的結構性存款產品 (III)認購北京銀行（方莊支行）的結構性存款產品 認購該等結構性存款產品 茲提述本公司日期為2025年3月31日的公告（「該公告」），內容有關（其中包括） 本公司認購北京銀行（方莊支行）及北京銀行（大興支行）的結構性存款產品。 誠如該公告所披露，於2025年3月31日，本公司訂立(i)北京銀行（大興支行）結構 性存款產品協議，同意使用其來自A股公開發行的臨時閒置募集資金認購北京 銀行（大興支行）的結構性存款產 ...

Core Viewpoint - Spring Medical's stock has experienced significant fluctuations, with a year-to-date increase of 115.12% but a recent decline of 2.04% on November 11, 2023, indicating potential volatility in the market [1]. Company Overview - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, specializes in the research, production, and sales of implantable orthopedic medical devices, including joint prosthetics and spinal implants [1][2]. - The company's main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal fixation systems [1]. Financial Performance - For the period from January to September 2025, Spring Medical reported a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, which is a 213.21% increase compared to the previous year [2]. - Since its A-share listing, Spring Medical has distributed a total of 359 million yuan in dividends, with 309 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Spring Medical increased by 4.12% to 6,164, while the average number of tradable shares per shareholder decreased by 3.95% to 46,906 shares [2]. - Notable new institutional shareholders include Hong Kong Central Clearing Limited and China Europe Economic Growth Mixed A, holding 2.9585 million shares and 2.8326 million shares, respectively [3].

Core Viewpoint - Spring Medical experienced a decline of 2.38% in stock price on November 7, with a trading volume of 83.6 million yuan, indicating potential market volatility and investor sentiment concerns [1] Financing Summary - On November 7, Spring Medical had a financing buy-in amount of 7.79 million yuan and a financing repayment of 8.40 million yuan, resulting in a net financing outflow of 0.62 million yuan [1] - The total financing and securities balance as of November 7 was 47.58 million yuan, which represents 0.62% of the circulating market value and is above the 90th percentile level over the past year, indicating a high financing balance [1] - No shares were sold or repaid in the securities lending market on November 7, with a total securities lending balance of 0, which is also above the 80th percentile level over the past year, suggesting a lack of short-selling activity [1] Company Overview - Beijing Spring Medical Equipment Co., Ltd. specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants [2] - The company was established on February 12, 1998, and went public on December 30, 2021, with a revenue composition of 99.89% from medical device products [2] - As of September 30, 2025, Spring Medical reported a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, reflecting a significant increase of 213.21% year-on-year [2] Dividend and Shareholder Information - Since its A-share listing, Spring Medical has distributed a total of 359 million yuan in dividends, with 309 million yuan distributed over the past three years [3] - As of September 30, 2025, the company had 6,164 shareholders, an increase of 4.12% from the previous period, with an average of 46,906 circulating shares per shareholder, a decrease of 3.95% [2][3] - Notable institutional shareholders include Hong Kong Central Clearing Limited and China Europe Economic Growth Mixed Fund, both of which are new entrants among the top ten circulating shareholders [3]

Core Viewpoint - Spring Medical experienced a decline of 2.38% in stock price on November 7, with a trading volume of 83.6 million yuan and a total market capitalization of 10.21 billion yuan [1] Company Overview - Spring Medical is a leading domestic manufacturer of orthopedic medical devices, focusing on the research, production, and sales of implantable orthopedic medical devices, including oral metal and invisible orthodontics, as well as oral implants and restorations [2][5] - The company is recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which signifies its strong innovation capabilities and high market share in niche markets [3] - The company is located in Tongzhou District, Beijing, and was established on February 12, 1998, with its stock listed on December 30, 2021 [7] Product Portfolio - Spring Medical's main products include joint prosthetics and spinal implants, covering major human joints such as hip, knee, shoulder, and elbow, as well as a full range of spinal internal fixation systems [2][8] - The company has developed products such as hip and knee surgical robots and medical image processing software for surgical planning, indicating its investment in smart medical technology [2][3] Financial Performance - For the period from January to September 2025, Spring Medical achieved a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a year-on-year increase of 213.21% [8] - Since its A-share listing, the company has distributed a total of 359 million yuan in dividends, with 309 million yuan distributed over the past three years [8] Shareholder Structure - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited and China Europe Economic Selection Mixed A, both of which are new shareholders [9]

Core Viewpoint - Spring Medical has experienced a decline in stock price, with a cumulative drop of 7.83% over the past five days, closing at 26.62 yuan per share on November 7, 2023, with a total market capitalization of 10.211 billion yuan [1] Company Overview - Beijing Spring Medical Co., Ltd. was established on February 12, 1998, and went public on December 30, 2021. The company specializes in the research, production, and sales of implantable orthopedic medical devices [1] - The main products include joint prosthetics and spinal implant products, covering major human joints such as hip, knee, shoulder, and elbow, as well as a full range of spinal fixation systems [1] - The company's revenue composition is primarily from medical device products (99.89%), with a minor contribution from other sources (0.11%) [1] Fund Holdings - Rongtong Fund holds a significant position in Spring Medical, with its Rongtong Healthcare Industry Mixed A/B Fund (161616) owning 1,102,600 shares, representing 3.27% of the fund's net value, making it the tenth largest holding [2] - The fund has incurred a floating loss of approximately 716,700 yuan today and a total floating loss of 2,491,900 yuan during the five-day decline [2] Fund Manager Performance - The fund manager, Wan Minyuan, has a tenure of 9 years and 76 days, with a total fund size of 5.957 billion yuan, achieving a best return of 139.47% and a worst return of -21.98% during his tenure [3] - Co-manager Liu Xiyang has been in position for 1 year and 238 days, managing a fund size of 839 million yuan, with a best return of -3.58% and a worst return of -4.4% [3]

Core Viewpoint - Spring Medical experienced a stock price decline of 2.13% on November 7, with a current price of 26.69 CNY per share and a market capitalization of 10.237 billion CNY [1] Company Overview - Beijing Spring Lida Medical Devices Co., Ltd. was established on February 12, 1998, and went public on December 30, 2021. The company specializes in the research, production, and sales of implantable orthopedic medical devices, including joint prosthetics and spinal implants [2] - The main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal fixation systems. The products are exported to various regions including Asia, South America, Africa, Oceania, and Europe [2] - The revenue composition is primarily from medical device products (99.89%) with a minor contribution from other sources (0.11%) [2] Financial Performance - For the period from January to September 2025, Spring Medical reported a revenue of 755.6 million CNY, representing a year-on-year growth of 48.75%. The net profit attributable to the parent company was 192 million CNY, showing a significant increase of 213.21% year-on-year [2] - Since its A-share listing, the company has distributed a total of 359 million CNY in dividends, with 309 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 4.12% to 6,164, while the average number of circulating shares per person decreased by 3.95% to 46,906 shares [2] - Notable institutional shareholders include Hong Kong Central Clearing Limited, which is the fourth-largest shareholder with 2.9585 million shares, and China Europe Economic Growth Mixed Fund A, which is the fifth-largest with 2.8326 million shares, both being new shareholders [3]